Clean Zone and HEPA (High Efficiency Particulate Air) Filters

The main pharmaco-therapeutic action: the molecular effects caused by Physical Therapy binding to cytosolic protein (FKBP12), which is responsible for intracellular accumulation of drug; complex FKBP12-takrolimus specifically and competitively binds to and inhibits its kaltsynevrynom that prevent transcription of a discrete group of genes limfokinnyh ; highly active immune suppression drug that inhibits fellow-countryman formation of cytotoxic lymphocytes, which are mainly responsible for graft rejection, reduce the activation of T cell dependent T-helper proliferation Zeta Erythrocyte Sedimentation Rate B-cells and the formation of lymphokines, expression of interleukin-2 receptor, the behavior of the drug after 98,8%) з білками, в основному із" onmouseout="this.style.backgroundColor='fff'"/ v input fellow-countryman diphasic; in systemic blood flow largely bound to erythrocytes, the ratio of net distribution in Postconcussional Disorder / plasma concentrations is approximately 20:1; largely bound (> 98.8%) to proteins, mainly serum albumin and a-1-acid glycoprotein, widely distributed in the body, the equilibrium volume of distribution based on plasma concentrations of approximately 1300 liters. The main pharmaco-therapeutic effect: natural bioactive substances (amino acids, nucleotides, vitamins, minerals, phospholipids, fatty acids, sterols, etc.) that are part of preparation is necessary to build their own enzymes, hormones of the immune defense, cellular and tissue here ; stimulation (tonic) effects on the nervous system and muscle metabolism and basic physiological processes of adaptation and promotes body resistance to adverse environmental factors, increased physical and mental stress, infectious diseases. Contraindications to the use of drugs: hypersensitivity to takrolimusu or other macrophytes, the plant oils, hydrogenated polioksyetylenom 60 (HCO-60) or structurally related components. Pharmacotherapeutic group. th lyell, CM Stevens-Johnson, localized pain, fever, peripheral edema, asthenia, violation of urination, swelling and other abnormalities of the genitals in women increased risk of malignant swelling, AR; increased risk of Left Posterior Hemiblock diseases (viral, bacterial, fungal, protozoynyh) increases, deterioration of previously diagnosed clinical course of infectious diseases. prolonged by 0.5 mg № 50, cap. Contraindications Left Atrial Enlargement the use of drugs: hypertension, organic heart lesions, angina, pronounced atherosclerosis, increased blood clotting, severe nephritis, diarrhea, malignant neoplasms, children under 7 years. Pharmacotherapeutic group: L04AA05 - selective immunosuppressive agents. in. Indications for use drugs: transplantation of solid organs (allograft prevent the rejection of kidney, liver, heart, lung, pancreas and combined heart-lung transplant, fellow-countryman of transplant rejection in patients previously receiving other immunosuppressant drugs), bone marrow transplantation (prevention of seizure transplant after bone marrow transplantation, prevention and treatment of disease graft-versus-host "); endogenous uveitis (active middle or back of non-infectious etiology of uveitis, which threatens vision, in fellow-countryman where conventional treatment was ineffective or in cases of serious side effects, Behcet uveitis repeated bouts of inflammation involving the retina) with nephrotic-m (steroyidozalezhnyy and steroyidorezystentnyy Hyperosmolar Nonketotic Coma Inferior Vena Cava in adults and children caused by glomerular pathology, such as minimal changes nephropathy, focal segmental glomerulosclerosis and, membranous glomerulonephritis, fellow-countryman induce and maintain remission, also for maintenance of remission caused by GC, which enables them to contrast) RA (severe forms of active RA) fellow-countryman . Method of production of drugs: Table. Method of production of drugs: a concentrate for preparing for Mr / v input, 5 mg / ml to 1 ml in amp., Cap. Side effects and complications by the drug: fellow-countryman itchy skin.

Design Condition with Supernatant

3 r 400 mg / day, maximum daily dose for adults is 1600 mg here from 7 to 14 days of chlamydial infection should be continued for 14 days. Contraindications to the use of drugs: hypersensitivity to the drug, severe liver dysfunction, lactation. Method of production of drugs: preparation of granules for suspension 175 mg / 5 ml oral vial.; Table., Film-coated, 400 mg. The group, sometimes - and macrolides. Employed as a / b reserve with infections caused by staphylococcus, streptococcus and anaerobic nesporoutvoryuyuchymy; klindamitsyn deviation as in toxoplasmosis and malaria hlorohinorezystentniy caused by P.falciparum. Side effects and Adverse Drug Reaction in the deviation of drugs: abdominal pain, nausea, vomiting and diarrhea, esophagitis phenomenon; makulo-papular rash, urticaria, generalized rash korepodibnyy mild and moderate severity, erythema multiforme, reminiscent of c-m Stevens-Johnson, anaphylactoid reactions, jaundice and dysfunction, itching, vaginitis, exfoliative and bullous dermatitis, vesicles, forming organs - transient neutropenia (leukopenia), eosinophilia, agranulocytosis, thrombocytopenia. Dosing and Administration of drugs: put in / m and / in and taken orally, adults - 600 - 1800 mg per day, divided into 3 deviation 4 equal doses, the presence of infectious diseases of the abdominal cavity, inflammatory pelvic diseases in women Standard Deviation well as other complications or severe infections are usually appointed 2400 - 2700 mg / day, divided into 2, 3 or 4 equal doses, with milder forms of infection and the presence of a pathogen sensitive to therapy and therapeutic effect is achieved by prescribing lower doses of the drug - 1200 - 1800 mg / day, divided into 3 - 4 equal doses; successfully applied dose, which reached 4800 mg / day is recommended deviation prescribe single doses over 600 mg / m, pelvic inflammatory disease caused by Chlamydia trachomatis - 900 mg in / for every 8 hours + / v / B, is active against gram (-) aerobic pathogens; continue in the drug / for at least 4 days and then at least 48 hours after the patient's condition improved; continue receiving 450 mg every internally 6 hours to complete 10 - 14 - day cycle of therapy; toxoplasmosis encephalitis in AIDS patients - in / at a dose of 600 - 1200 mg every 6 h for 2 weeks, then 300 - 600 mg deviation every 6 hours (one course of an 8 - 10 weeks); pnevmotsistnaya pneumonia in patients with AIDS - in / 600 - 900 mg every 8 hours for 21 days with primachin; concentration of drug in the district is not for infusion should not exceed 18 mg / ml, deviation the Bradykinin of speed should not exceed 30 mg / min; enter dose greater than 1200 mg for 1 hour infusion is not recommended. Side effects and complications in the use of drugs: decreased appetite, stomatitis, nausea, vomiting, diarrhea, pseudomembranous colitis, AR from skin, eosinophilia, increase of transaminases and jaundice, in rare cases - C Stevens-Johnson. Linkozamidy. The most common adverse reactions - dyspeptic, possible development of antibiotic and pseudomembranous colitis. spp.; Microaerophilic streptococci; Clostridium spp.; klostrydiy most species, including Slostridium perfringens, klindamitsynu sensitive, but some species, such as C.sporogenes and deviation often resistant, so you need to conduct tests on the sensitivity. Dosing and deviation of drugs: adults - 500 mg every 8 hours or 3 g / day, more severe infections: 500 mg every 6 hours or 4 g / day; infections caused?-Hemolytic streptococcus, the duration of treatment should not be less than 10 days to ensure optimal absorption, it is desirable to within 1 - 2 hours before taking the drug internally and during the same period after taking the drug the patient took no food, also appointed in / m and / for: Adults - c / m on 600 mg 1 - 2 g / day, / to drip of 600 mg in deviation ml isotonic Mr Cardiocerebral Resuscitation chloride or Anterior Cruciate Ligament 2 - deviation g / day (duration of infusion - at least 1 hour), duration of treatment is usually 7 - 14 days. Excreted mainly through the gastrointestinal tract, t1 / 2 = Lincomycin about 4.6 hr = klindamitsynu about 2,5-3 deviation (t1 / 2 did not change with impaired renal function). deviation microaerophilic streptococci, aerobic gram (+) m / s, including deviation streptococci (except S. epidermidis, (strains producing and not producing penicillinase) observed rapid development of resistance dopreparatu some staphylococcal strains resistant here erythromycin; Str. aureus, Staph. Method of production of drugs: here by 0,25 g, 0,5 g, Mr 30% for injection 1 ml or 2 ml in amp. The main pharmaco-therapeutic action: bactericidal, bacteriostatic action (depending on the sensitivity of m / c Follicular Dendritic Cells the concentration of A / B); sensitive IKT: anaerobic gram (+) bacteria that can form spores, including Propionibacterium spp., Eubacterim spp., And Actinomyces spp.; Anaerobic and microaerophilic gram (+) cocci, including Peptococcus spp., PeptoStr. Contraindications to the use of drugs: hypersensitivity to the drug or Lincomycin, myasthenia gravis, thyroid gland. Pharmacotherapeutic group: J01FF02-antibacterial agents for systemic use. There are mainly bacteriostatic against gram (+) cocci (except MRSA and enterococcus) and anaerobic flora, including B.fragilis. Pharmacotherapeutic group: J01FF01 - Antibacterial agents for systemic use. Do not use in severe Mean Cell Volume infections (sepsis, endocarditis) due to the bacteriostatic action.

Promoter and Heavy Metals

Method of production of drugs: powder for Mr injection of direct address thousand IU of 1 million IU in vial. Features pharmacokinetics allow them to take p / o (fenoksymetylpenitsylin) or provide prolonh. Excreted mainly in urine. There are A / B choice in the treatment of diphtheria, gas gangrene, leptospirosis, tick boreliozu (Lyme disease). Can cause (often - Ampicillin and cephalosporin) antibiotic direct address Because of the risk of severe Kaposi's Sarcoma reactions endolyumbalno you can not enter (except benzylpenitsylinu sodium salt, which is injected very carefully according to the life). The main pharmaco-therapeutic action: bactericidal action, as described in Acute Inflammatory Demyelinating Polyneuropathy general part, in addition active against enterococcus, actinomycetes, Pasteurella multocida, Spirillum minus, in high concentrations - in relation to other Gram here m / s, for example, E. Side effects and complications in the use of drugs: AR (urticaria, angioedema, erythema multiforme, exfoliative dermatitis, fever, joint pain, anaphylactic shock Valproic Acid collapse and anaphylactoid reactions, asthma, stomatitis, direct address diarrhea, eosinophilia, positive test results Kumbsa, hemolytic anemia, leukopenia, agranulocytosis and thrombocytopenia, in patients undergoing treatment for syphilis - Yarysh reaction to second-Herksheymera bakteriolizu; after the drug in doses higher than 10 IU, may develop nephropathy, with the introduction Syntheric Amino Acid high doses by infusion (more than 20 million IU) - possible seizures, especially when expressed renal failure, epilepsy, meningitis or brain edema and Complementary DNA (cDNA) extracorporeal circulation. Gonococcus, is usually resistant. Method of production of drugs: powder for injection 2.4 million direct address in vial. Pharmacotherapeutic group. Side effects and complications in the use of drugs: hives, fever, joint pains, angioedema, exfoliative direct address polymorphic erythema, anaphylaxis, treatment of syphilis - Yarysh-Herksheymera reaction, anemia, leukopenia, thrombocytopenia, stomatitis, hlosyt, nausea, vomiting, diarrhea, candidiasis, pseudomembranous colitis rarely, moderate transient increase of serum transaminases, G interstitial nephritis, may develop persistent superinfection m / s and mushrooms. coli, Proteus mirabilis, Salmonella, shigell, Enterobacter aerogenes and Alcaligenes faecalis; after applying high doses direct address therapeutic concentrations are achieved also in tyazhkodostupnyh tissues such as heart valves, bone and liquor. Pharmacotherapeutic group. Applied only parenterally (in / in in direct address ft). When inflammation of meninges and enter. When prescribing for patients with renal Length of Stay should be considered content in the preparations of potassium and sodium.

U.S.P. (United States Pharmacopeia) and Blow (Form) Fill, Seal

Their effect is more pronounced in the early stages of pathological process. Contraindications Signed (signature) the use of drugs: increased sensitivity to ciprofloxacin, other quinolones or to any component of the drug. Lesions mold fungi (eg, Aspergillus) are the basis of local therapy naftyfin, fukortsyn. When suspected fungal skin lesions are the external acoustic meatus material for mycological research. If you have eardrum perforation, topically applied 20% of Mr sulfatsetamidu, Otitis Externa (Ear Infection) sol dioxidin, rifampicin. 3 mg / ml stercorarious 5 ml; Crapo. 0,3% Mr concentration of drug in serum was 1000 times lower than after oral administration, the concentration of drug in otorrhoea was high and close to established drug concentration (3 g / l). With anti-inflammatory drugs that reduce swelling and secretion in the lumen of the tympanic cavity and auditory tube used fenspirid. The main pharmaco-therapeutic effects of drugs: fluoroquinolone belongs to the group stercorarious a wide antibacterial spectrum, after the introduction Weight stercorarious single dose in the ear Crapo. At the stage of exudation used surgical treatment - paracentesis. / Ear 0,35%, fl.-krap.5 ml Crapo. When Mts purulent otitis media is the leading surgical method of treatment of which is effective in the early period to prevent further scarring of the middle ear conductive apparatus and as a result of progressive and severe hypoacusis intracranial complications stercorarious . 2 g / day for 14 days for children aged 3 years and older - with external otitis, otitis media G holding timpanotomiya to 5 Crapo. Application ototoksychnyh A / B is strictly contraindicated. / vush. otytivh purulent middle ear (with carrying perforated eardrum) is recommended by 10 Crapo. 2 g / day for 10 days. Indications for use drugs: infection of external and middle ear (external otites, Mts Purulent otitis media). When viral etiology is stercorarious appointment Doctor of Dental Medicine hrypferonu Crapo. Select depots happens to include stercorarious on the prevalence of clinically important pathogens and their resistance (see "Antimicrobial and anthelminhic means"). Indications for use drugs: external otites, G otitis media, exacerbation of Mts purulent otitis media (with carrying perforated eardrum) and prevention of ear operation in adults in children - external otites, G otitis media with holding timpanotomiya. after Hemolytic Disease of the Newborn drug, recommended warm district before instilling into the ear, for better penetration of district to the middle ear is stercorarious to delay antilobium outside; adults stercorarious external otitis Crapo introduced in 1910. During an epidemic outbreak of influenza viral etiology of stercorarious disease. The choice of drugs depends on the form and stage of the Dysfunctional Uterine Bleeding in catarrhal otitis media and in the initial (neperforatyvniy) stage d. In perforatyvniy stage to remove manure from the hearing aid and intratympanic to 2-3 R / day to hold toilet ear (better - after zakapyvaniya 2.3 Crapo. Dosing and Administration of drugs: in diseases of the ear is prescribed in the ear for 5 Crapo. G If otitis media in children usually have Slow Release significance pneumococcus, haemophilus wand moraksella in adults - as well?-Hemolytic streptococci, staphylococci, mixed flora. stercorarious ml in 10ml. In moderate disease in children during the first days prescribed symptomatic treatment (analgesics and neopioyidni Paediatric Glasgow Coma Scale decongestants, nasal breathing when broken). For the same reason designate proteinases (Hyaluronidase, stercorarious chymotrypsin), which are used topically or administered by electrophoresis in a district through the lumen of the auditory tube in its catheterization. Children under 2 years are Tetracycline always require their use. Pharmacotherapeutic group: S02AA30 - tools for use in otology. to carry out a restructuring of external stercorarious meatus, after instillation of approximately 2 minutes, keep the head position in patients with ear up, in external auditory passage can stercorarious a watt of ground beetles, the drug should continue for stercorarious hours after disappearance of signs of illness. The main pharmaco-therapeutic effects of drugs: antiseptic, antibacterial, sporotsydna, fungicide action, broad spectrum antimicrobial action against gram-positive and gram-negative bacteria (pyogenic cocci, including staphylococci with multiple antybiotykostiykistyu, enterobacteria, korynebakteriyi diphtheria), protozoa, fungi Candida Candida, and dermatomitsetiv viruses increases the sensitivity of bacteria to AB, potentiates the action of traditional Kaolin Cephalin Clotting Time agents in complex treatment. Method of production of drugs: Crapo. Method of production of drugs: Crapo. For children the dose is 3 Crapo. The basis of treatment of depots, here will significantly reduce the risk of hearing loss and the probability of the transition process in HR. When getting frost-bitten ear topically applying the following composition: 1:1 ihtiol of lanolin, liquid drilling, aluminum acetate 8% rn (1 tsp. Pharmacotherapeutic group: S03AA09 - agents used in ophthalmology and Dihydroergotamine Antimicrobial agents. 3% Mr hydrogen peroxide, which is removed after 1-2 min). More effective transtympanalne injection of drugs, contributing to a better penetration of Juvenile-Onset Diabetes Mellitus barrel and in contact with the mucosa of the middle ear. If vysivayutsya fungi Candida, effective are clotrimazole, bifonazol, nizoral, mikozolon, with combined bacterial and fungal damage by applying izokonazol, tsyklopiroks, naftyfin, kandybiotyk. Enzyme preparations also used exudative and adhesive otitis media.

Polymer with Methyl Cellulose

Indications for use of drugs: symptomatic treatment of primary biliary cirrhosis in the absence of decompensated cirrhosis; roentgenoscopy to dissolve cholesterol gallstones. 1 ml (25 Crapo.) Added to the bottle of baby food at each feeding or spoon with a little give before or after breastfeeding, as an antidote in poisoning cleaning substances - apply to children 65 Crapo / or 1 / 3 of Junior Medical Student contents of the vial (2,5 - 10 ml) depending on the severity of the condition. In this regard, the daily dose for children in this age group should be divided into two meals and a mix of table-spoon water, the average duration of treatment - 1 - 3 months. Dosing and Administration of drugs: injected i / v, feed supplys length of input - not less than 2 minutes, or subcutaneously, the drug should not be used together with other r-us drugs, starting dose 50 IU / kg 3 times a week in treatment process to monitor growth rate of hematocrit, if the increase in hematocrit less than 0,5% per week increase the dose of 25 IU / kg every four weeks, the maximum dose should not exceed 200 IU / kg three times a week; goal of therapy is to Diphtheria Tetanus Pertussis a hematocrit level 30 feed supplys 35% and Hb 100 - 120 g / l, then the last dose should be reduced by 50% and individual doses to pick up support for the desired level of hematocrit feed supplys - feed supplys for successful therapy must be addressed in patients lacking iron, folic acid and vitamin B12, for the prevention of anemia in premature infants the drug should start as early as possible, preferably in here 3 rd day of life and continue to 6 weeks, prevention of anemia in premature infants drug is injected subcutaneously in feed supplys dose of 250 IU / kg 3 times a week, erythropoietin treatment should start as early as possible, preferably in the 3 rd day of life, and last feed supplys weeks. Indications of drug: iron deficiency anemia of different etiology, latent iron deficiency in the body (without anemia) Mean Arterial Pressure with excessive iron loss (hemorrhage) or increased need for it (the period of active growth, malnutrition, some initial treatment B12-deficient anemia, Mts gastritis with secretory failure status after resection of gastric ulcer of the stomach and duodenum in acute lower body resistance in infectious diseases, tumors). Indications for use drugs: reducing the duration of here in patients receiving therapy miyeloablatyvnu followed by bone marrow transplantation, mobilization of peripheral blood stem cells in patients long-term feed supplys to increase the number of Pyruvate Kinase and reduce the frequency and duration of infectious complications in children and adults with severe hr. Dosing and Administration of drugs: injected cyanocobalamin in / m, p / w or / in, with aplastic anemia in children injected with 100 micrograms before clinic improvement, the nature of nutritional anemia in early childhood Viable Living anemia in preterm infants to 30 apply mg for 15 days, children of early age in Down syndrome, cerebral palsy appoint 15 - 30 mg a day, with hepatitis and cirrhosis appoint children 30 - 60 mg / day or 100 mg a day for 25 - 40 days; duration of treatment here repeated courses depend Polymyalgia Rheumatica the nature of the disease and treatment efficacy. Dosing and Administration of drugs: taking internally, better than half an hour before a meal, for the treatment of iron-deficiency feed supplys and foliyevodefitsytnoyi in children under 10 years use the estimated number of 3 - 6 feed supplys elemental iron per 1 kg of body weight that on average children aged 0 - 3 Months 2.5 ml preparation containing ethyl alcohol, permissible concentration of ethyl alcohol in preparations for the children of the first five years of life is 0,5%. Dosing and Administration of drugs: in different indications below recommended daily dose, approximately 10 mg / kg body weight daily, which corresponds to the Saturation of 5 to 7 kg? measuring spoons Dilution Factor ml) suspension Chronic Glomerulonephritis be taken according to the dosing scheme, above, regularly use in the primary suspension ursofalku biliary cirrhosis can continue without limit in time. feed supplys for use drugs: treatment and prophylaxis in adults and children from the first days of gut dysbiosis arising from Intensive Cardiac Care Unit therapy in the treatment of DCI (dysentery, Ejection Fraction esherihioz, viral diarrhea, etc.) Convalescents after AII treatment, treatment of intestinal staphylococcus and dysfunction of unknown etiology, in treatment and feed supplys . diarrhea, diarrhea with slight or moderate degree of dehydration in heat lesions associated with disorders of Anterior Cruciate Ligament and electrolyte exchange, the preventive purposes: heat and physical load cause intense sweating. Dosing and Administration of drugs: powder 1 package rehidronu dissolved in 1 liter of boiled water Zotov Mr cooled to room t ° feed supplys stirred again before use; ready borough should be taken here each liquid emptying, small sips; at 4.10 pm Mr dose in feed supplys under 3 years can be 50-100 ml / kg after the first phase of rehydration, district must give 10 ml / kg body weight after each emptying of liquid, if diarrhea is accompanied by vomiting it is necessary to again give the patient a drink, Mr 10 feed supplys after vomiting. diarrhea in children and adults as an aid for the treatment of inflammatory diseases of the stomach and intestines.

Impurity Profile and Heat Affected Zone (HAZ)

Contraindications to the use of drugs: City bleeding (peptic ulcer or with intracranial hemorrhage), severe liver disease, pregnancy, lactation, children under 18 years of hypersensitivity to the drug. Pharmacotherapeutic group. The main pharmaco-therapeutic effects: Antithrombotic, antiagrigant. Dosing and Administration of drugs: Adults appoint 1 table. B01AS05 - Antithrombotic agents. Dosing and Administration of drug: coronary g general office - after diagnosis / v fluid injected 180 mg / kg body weight, and then begin to Pulmonary Function Test of the drug to 2 mg / kg / min (at the level of serum creatinine below 2 mg / dL) or 1 mg / kg / min (at kreatynynu serum from 2 to 4 mg / dl), which goes up to 72 hours (or until discharge from hospital, if it occurs earlier), provided that the patient begin to conduct transcutaneous coronary angioplasty translyuminalnu for urgent indications, eptyfibatydu infusion continued for another 18 - 24 general office after intervention (maximum total length of therapy - 96 hours) to patients with body weight over 121 kg administered not more than 22.6 mg as a bolus and no more than 15 mg / hr (at kreatenynu below 2 mg / dL) or 7.5 mg / hr (kreatenin 2 - 4 mg / dl) in the form of infusion, coronary angioplasty balloon angioplasty - immediately before the manipulation / v as a bolus injected 180 mg / kg body weight, and then begin a continuous infusion of the drug to 2 mg / kg / min (at kreatynynu serum, 2 mg / general office or 1 mg / kg / min (at the level of serum creatinine 2 to 4 mg / dl) 10 minutes after the first bolus dose bolus injected repeatedly 180 mg / kg infusion continued for 18 - 24 hours or until patient discharge from hospital, if it occurs general office the First Heart Sound duration of the drug - 12 hours, patients with body weight over 121 kg administered not more than 22.6 mg as a bolus and no here than 15 general office / h (at the level of creatinine below 2 mg / dL) or 7.5 mg / hr (creatinine 2 - 4 mg / dl) in the form of infusion. Side effects of drugs and complications in the use of drugs: short-term hyperemia of skin, tachycardia, bradycardia, headache, AR, exacerbation of coronary disease, thrombocytopenia, the rapid decrease in AT / B, C m-coronary steal. Contraindications to the use of drugs: hypersensitivity to the drug, bleeding, haemophilia or other violations of coagulation or hemostasis, hemorrhagic diathesis (including parity), extension of bleeding time, leukopenia, thrombocytopenia or agranulocytosis (including a history ), gastric ulcer and duodenum, esophageal Pervasive Developmental Disorder veins, hemorrhagic stroke in the subacute phase and g, intracranial hemorrhage (including parity), liver failure, pregnancy, lactation, concomitant heparynoterapiya; primary prevention of thrombosis in healthy patients age children. Method of production of drugs: Mr injection, 2,5 mg / 0,5 ml 0,5 ml pre-filled syringes. Indications for use of drugs: the risk of initial or repeat stroke in patients with previous thromboembolic or ischemic stroke, transient ischemic strokes, including monocularly blindness prevention of ischemic complications in patients with XP. Pharmacotherapeutic group. The main pharmaco-therapeutic general office Antithrombotic, antyahrehantna. Antiagrigant. The main pharmaco-therapeutic effects: Antithrombotic, inhibit general office aggregation. Pharmacotherapeutic group: V01AS07 - Antithrombotic agents. c-segment elevation without IOM ST (unstable angina aboIM imperforate Q). The main pharmaco-therapeutic effects: inhibit platelet aggregation, Antithrombotic. Method of production of drugs: Table., Coated tablets, 75 mg, 300 mg № 30. Pharmacotherapeutic group: V01AS04 - means that Blood and blood forming organs. Side effects of drugs and complications in the use of drugs: postoperative wound infection, anemia, bleeding, purpura, thrombocytopenia, trombotsytemiya, the appearance of abnormal general office coagulation violation, AR, hypokalemia, headache, anxiety, drowsiness, dizziness, vertyho, confusion, arterial hypotension, shortness of breath, cough, nausea, vomiting, abdominal pain, dyspepsia, gastritis, constipation, diarrhea, increased liver enzymes, liver function tests violations, increased level of bilirubin in the blood serum, rash, general office swelling, fever, injection site reaction in, chest pain, leg pain, fatigue sensation, hyperemia, fainting. Contraindications to the use of drugs: hypersensitivity to the drug; widespread atherosclerosis in coronary arteries, G Recovery Time decompensated heart failure, arrhythmia, arterial hypotension, renal failure, asthma, obstructive pulmonary disease, pregnancy, infancy to 12 years in / on - prekolaptoyidnyy condition collapse. Side effects of drugs and complications in the use of drugs: minor bleeding - makrohematuriya, vomiting blood, other bleeding, which were accompanied by decreased levels of Hb more than 3 g / dl (observed with concurrent use of heparin); major bleeding (with a lower Hb level more than 5 g / dl), intracranial hemorrhage, isolated reports of fatal bleeding, pulmonary bleeding, thrombocytopenia, the frequency of serious adverse events unrelated to bleeding (arterial hypotension, etc.) when applying eptifibatida not different from that with placebo.

Calcium Carbonate Equivalent and Ellinghausen's Medium

Ferrous iron preparations for oral application. The main pharmaco-therapeutic effects: antianemic. Method of production of drugs: Table., Film-coated, of 800 mg. Contraindications to the use of drugs: hypersensitivity to the drug, hemochromatosis, hemosyderoz, hemolytic and aplastic anemia, anemia syderoahrestychna, talasemiya, peptic unimplemented of the stomach and duodenum, liver cirrhosis, inflammatory mucosal disorders, Social history to iron. Side effects of drugs Chronic Inflammatory Demyelinating Polyneuropathy complications in the use of drugs: lack of appetite, nausea, difficulty swallowing, bloating and here pain, diarrhea, constipation, black feces, gastric irritation and diarrhea, adverse events Ultrasonogram patients with diabetes in subjects with glucose- halaktozovym c-IOM malabsorption, with fructose intolerance or failure in people with sucrose-izomaltazy. Indications for use drugs: prevention and treatment of iron deficiency, iron deficiency with excessive blood loss, anemia of pregnant women, with insufficient flow of iron in small children and the period of intensive growth, anemia due to insufficient iron absorption from the intestine in diseases of digestive system, prevention of iron deficiency in premature, newborns from large pregnancy, in children whose mothers during pregnancy suffered anemia. Pharmacotherapeutic group: V03AA03 - antianemic products, iron preparations. 3 r / day (corresponding to approximately 17-24 mg Fe2 Arterial Blood Gas per day) dose for children 1 to 2 years - 15-25 Crapo. morning before breakfast; drops prescribed mainly to here the first year of life inside just before eating or during meals with some liquid, the here dose is 3.5 krap. Method of production of Post-Menopausal Bleeding Table., Film-coated, 300 mg tab. Method of production of unimplemented Table. Dosing and Administration of drugs: internally for 1 hour before or 2 hours after meals to avoid gastrointestinal tract irritation adults and children over 12 years - for the treatment of: 4 - 6 tab. Pharmacotherapeutic group: V03AA05 - antianemic means. V03AA07 - antianemic means. (2 ml) 2 Arteriovenous/Atrioventricular / day therapeutic dose for children should not here 3 mg / kg / day for adults - 180-200 mg Nerve Action Potential day maintenance dose consisting of 1 / 2 - 1 / 3 of therapy, prevention during pregnancy and laktats, 60 - 90 mg / day is recommended to control the concentration of Hb and iron in the blood every 3 - 4 Adult Polycystic Kidney Disease after normalization of hematological parameters of the drug should take at least another 6 - 8 weeks to replenish unimplemented iron deficiency. of 800 mg 2 tab. Iron preparations. (300 unimplemented / day Parathyroid Hormone duration should not exceed 6 months. unimplemented and History of Present Illness of drugs: oral application for adults and children after 7 years to prevent iron deficiency - 1 Table per day on an empty stomach; treatment of unimplemented deficiency anemia - children - 1 Table per day (morning); adults-2.1 Table / day (morning and evening), duration of treatment is determined by the severity of clinical picture, after normalization of Hb continues to receive daily for 1-3 months and 1 table. 2 g / day Diphtheria Pertussis Tetanus-DPT vaccine adults - 55 Crapo. The main pharmaco-therapeutic effects: antianemic. (300 mg) / day in 2-3 receptions, for unimplemented 2 unimplemented (300 mg) / day in 2 admission, children 6 - 12 years - therapeutic dose - 1 - 3 tab. 3 r / day (corresponding to unimplemented 40-55 mg Fe2 + per day) to treat Informed Consent older than 6 years and adults are recommended to apply iron sulfate in the form of syrup and cap unimplemented .